Knott David M Jr Makes New Investment in Kura Oncology, Inc. $KURA

Knott David M Jr acquired a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) in the 3rd quarter, HoldingsChannel reports. The fund acquired 67,302 shares of the company’s stock, valued at approximately $596,000.

Other hedge funds also recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its position in shares of Kura Oncology by 392.8% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock valued at $34,000 after acquiring an additional 3,072 shares during the period. PNC Financial Services Group Inc. grew its holdings in Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after purchasing an additional 3,769 shares during the period. Tower Research Capital LLC TRC increased its stake in Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock valued at $70,000 after purchasing an additional 9,958 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in Kura Oncology in the second quarter valued at $80,000. Finally, Merit Financial Group LLC acquired a new position in shares of Kura Oncology during the third quarter valued at about $89,000.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 11,208 shares of Kura Oncology stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $94,819.68. Following the transaction, the insider directly owned 226,931 shares of the company’s stock, valued at $1,919,836.26. The trade was a 4.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Thomas James Doyle sold 7,142 shares of the company’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $60,421.32. Following the completion of the sale, the senior vice president owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. The trade was a 4.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 59,794 shares of company stock valued at $537,176 over the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Leerink Partners set a $20.00 price objective on shares of Kura Oncology and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Barclays reaffirmed an “overweight” rating and set a $28.00 price target (up from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. Wall Street Zen cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, January 22nd. Finally, Wedbush lowered their target price on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $27.71.

Key Headlines Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI early commercial traction — management reported $2.1M in net product revenue from ~5 weeks of sales and rapid payer coverage (~80% of private payers aligned to label), supporting near-term uptake expectations. Q4 & Corporate Update
• Positive Sentiment: Material milestone payments & cash runway — Kura recorded collaboration revenue and milestone receipts (including a reported $135M channel milestone and additional $30M payments tied to Phase 3 dosing) and ended 2025 with $667.2M cash plus ~$180M anticipated collaboration payments, which management says funds operations into pivotal Phase 3 topline results. This reduces near‑term financing risk. Q4 Financials
• Neutral Sentiment: Pipeline cadence: management flagged multiple 2026 data readouts and enrollment progress (pivotal KOMET‑017 frontline trials, KOMET‑007 combos, FIT‑001 expansion). These are potential future catalysts but carry binary clinical risk. Corporate Update
• Neutral Sentiment: Inducement grants: the company issued options for 44,700 shares to four new hires under Nasdaq rules — modest potential dilution and a routine hiring incentive. Inducement Grants
• Negative Sentiment: Q4 earnings and revenue miss — Kura reported a $0.92 loss per share vs. consensus -$0.72 and Q4 revenue of $17.3M vs. est. ~$34.7M. R&D and SG&A rose sharply, driving a wider net loss ($81M). These miss metrics explain selling pressure despite commercial progress. Earnings Recap
• Negative Sentiment: Safety profile and boxed warning remain material risks — differentiation syndrome, QTc prolongation and other serious AEs were highlighted in the label and trial experience; these safety issues can limit uptake, dosing, and label expansion. Safety & Label
• Negative Sentiment: Analyst note: Wedbush trimmed its price target from $38 to $36 (rating remains Outperform), a modest downgrade that may temper upside sentiment despite bullish coverage from other firms. Analyst Update

Kura Oncology Trading Up 5.3%

KURA opened at $8.96 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The firm has a market capitalization of $779.70 million, a PE ratio of -2.82 and a beta of 0.22. The company’s 50-day moving average is $8.75 and its 200 day moving average is $9.39.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.20). The business had revenue of $17.34 million during the quarter, compared to the consensus estimate of $34.71 million. Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 91.62%. As a group, research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.